Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Swarup Gupta headshot

Foreign Stock Roundup: BP Buys Cairn Energy Stake, Honda to Recall 900K Minivans

Investors across the world should brace for a volatile end to the month of November.

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, GlaxoSmithKline and Roche

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, GlaxoSmithKline and Roche

      Cancer Space Update: 2 Drugs Receive Regulatory Nod in EU

      This week the European Commission granted approval to Zejula for ovarian cancer and for label expansion of Tasigna in first-line Ph+ chronic myeloid leukemia.

        Will New Drug Approvals Boost Novartis (NVS) Portfolio?

        Novartis (NVS) is facing stiff generic competition for key drugs. Nevertheless, we expect approval of new drugs to boost its portfolio.

          Arpita Dutt headshot

          Pharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents Data

          Key highlights this week include the FDA approval of GlaxoSmithKline (GSK) and J&J's new HIV drug and study data from Roche.

            Puma Inks License Deal to Commercialize Cancer Drug Nerlynx

            Puma (PBYI) signs a licensing deal with Specialised Therapeutics Asia to commercialize its breast cancer drug Nerlynx in Australia, New Zealand and South East Asia.

              Parkinson's Space in Focus as Acorda Stops Tozadenant Trial

              Acorda scraps development of a key Parkinson's disease candidate, tozadenant. With the discontinuation, investors' focus once again shifts to the Parkinson's space.

                Global In Vitro Diagnostic Market Booms: Stocks in Focus

                With the emergence of complex and transmittable diseases worldwide, In Vitro Diagnostic within the MedTech space is currently in the spotlight.

                  Company News For Nov 21, 2017

                  Companies In The News are: DY,TWX,RHHBY,ITCI

                    Roche Reports Positive Data From Tecentriq Combination Study

                    Roche (RHHBY) announced encouraging results from IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin.

                      Swarup Gupta headshot

                      Foreign Stock Roundup: JD.com Beats Estimates, Petrobras & Infineon Miss

                      Political uncertainty in the United Kingdom and commodity prices weighed on Europe's stocks over last week.

                        Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion

                        Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.

                          Cancer Space Update: Label Expansion for Three Major Drugs

                          This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

                            Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval

                            Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.

                              Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?

                              Alnylam (ALNY) expects to achieve the profile of three marketed products by the end of 2020 and remains focused on development of its pipeline candidates.

                                Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test

                                Roche's (RHHBY) diagnostic portfolio gets a further boost with FDA's clearance for Ventana tests.

                                  Shire Gets Positive CHMP Opinion for Hemophilia A Drug

                                  Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

                                    Novartis (NVS) Arm's Biosimilars Study Results Encourage

                                    Novartis (NVS) generic arm, Sandoz, reported positive data from two phase III studies evaluating biosimilars of Humira and MabThera respectively.

                                      Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II

                                      Nektar (NKTR) and partner Bristol-Myers share positive interim data from dose-escalation part of a phase I/II study, evaluating NKTR-214 with Opdivo across three tumor types.

                                        Amgen Gets Positive CHMP Opinion to Expand Nplate's Label

                                        Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.

                                          Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat

                                          Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.

                                            Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss

                                            Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q3. However, shares were down in after-hours trading.

                                              Arpita Dutt headshot

                                              Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod

                                              Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.

                                                Inovio (INO) Q3 Loss Wider Than Expected, Revenues Miss

                                                Inovio (INO) reports wider-than-expected loss in Q3. Revenues decline year over year due to lower grants received from DARPA for development of Ebola vaccine.

                                                  Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus

                                                  Ophthotech (OPHT) reported better-than-expected third-quarter earnings and sales. The company continues to advance Zimura in several indications.